Binders (cholestyramine, clays)
What studies of binders (cholestyramine, clays) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Binders (cholestyramine, clays) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Binders (cholestyramine, clays) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Fatigue1 study · 1 (few people) person tried binders (cholestyramine, clays) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months (few people)
Fatigue improved.
The evidence is very uncertain about the effect of binders (cholestyramine, clays) on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months
- Outcome
- fatigue
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person tried binders (cholestyramine, clays) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of binders (cholestyramine, clays) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months
- Outcome
- Bell CFIDS disability scale
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person tried binders (cholestyramine, clays) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of binders (cholestyramine, clays) on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months
- Outcome
- reduction in symptoms
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Fatigue | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
900 mg at the start
- 2Top dose
Most often 900 mg (1 of 1 studies)
Doses across 1 study
900 to 900 mg.
Each study’s dose, as printed
- 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature. (2026)
All papers
- Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature.2026 · case report · 1 in the study
Summary
This single case report describes a 60-year-old female with long COVID who was examined at a gastroenterology outpatient clinic with chronic fatigue and autonomic dysfunction. There was no comparison group. Intestinal permeability was assessed with a carbohydrate absorption test at five different time points (IP Test 1–5), alongside fatigue and the Bell CFIDS disability scale. The patient received Innovall FD™ (Bacillus coagulans and Bacillus subtilis), one capsule containing 2.5 × 109 CFU twice daily for 3 months. During that time, her fatigue continued to subside, and the patient reported a reduction in symptoms, corresponding to an increase of around 20 on the Bell CFIDS disability scale from initial baseline of 40–60. Later, after symptoms and fatigue increased again (Bell CFIDS disability scale 40), she received medicinal clay (Luvos-Heilerde imutox™), 3 × 900 mg capsules (total 8.1 g/day) three times a day for 4 months. Within 6 months following the initiation of medicinal clay therapy, the patient experienced a remission of symptoms (Bell CFIDS disability scale 100), and in clinical follow-ups she remained in remission. The medicinal clay was discontinued to prevent potential malabsorption of nutrients associated with medicinal clay. The authors state that this is a single case report and generalizations cannot be made.